CLR 131 is a targeted small-molecule that is being developed for the treatment of myeloma and lymphoma, as well as pediatric and head & neck cancers. It works by delivering a radioactive, toxic compound directly to tumor cells, while limiting exposure to healthy cells. CLR 131 was granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission. We are talking to Dr. Sikander Ailawadhi, the lead investigator on several CLR 131 trials, to get his perspective on the potential and future of CLR 131 as an important addition to myeloma treatments.

Brain tumors can be among the most challenging cancers to treat. The blood-brain barrier, a natural defense mechanism that shields the brain from harm can also prevent cancer treatments from reaching tumors. However, immunotherapy, precision medicine, and the other new approaches to treatments have been able to get through these barriers and effectively reach tumors. We are discussing the latest in brain tumor research and treatment with neuro-oncologist Dr. Nancy Bush from UCSF Helen Diller Family Comprehensive Cancer Center.